Fresenius Kabi Oncology Ltd (FKONCO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532545 | NSE: FKONCO | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

Fresenius Kabi Oncology Ltd (FKONCO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532545 | NSE: FKONCO | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Fresenius Kabi Oncol

Based on:

M-Cap below 100cr DeciZen not available

Fresenius Kabi Oncology stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
2,254.9 Cr.
52-wk low:
132
52-wk high:
132.6

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Fresenius Kabi Oncol:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -8.1%4.3%6.8%-2.7%4.6%-40.5%6.7%4.8%5.4%7.3%-
Value Creation
Index
-1.6-0.7-0.5-1.2NANANANANANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 542624703660630603667717786813660
Sales YoY Gr.-15.2%12.7%-6.2%-4.5%-4.3%10.7%7.5%9.7%3.4%-
Adj EPS -3.40.22.90.82.5-4.6111.21.4-3.2
YoY Gr.-NA1731.3%-73.7%224.7%-282.4%NA-7.8%27.4%16.5%-
BVPS (₹) 25.925.826.923.923.93.525.626.627.829.434.3
Adj Net
Profit
-572.849.813.141.3-75.349.645.558.167.8-54
Cash Flow from Ops. 7.9-39.111298.4770-46023.7175-63.8-
Debt/CF from Ops. 53.1-13.34.34.76.232629.1-0.16.40.9-1.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 4.6%5.2%6.8%3.4%
Adj EPS NA-10.8%11%16.5%
BVPS1.4%4.2%4.7%5.7%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-11.90.611.1310.3-33.27.73.64.54.9-10
Op. Profit
Mgn %
1.113.919.113.814.813.614.811.214.615.8-16.5
Net Profit
Mgn %
-10.50.47.126.6-12.57.46.47.48.3-8.2
Debt to
Equity
11.211.11.210.200.10.10.1-
Working Cap
Days
438409427473507574604651618594305
Cash Conv.
Cycle
198185176168160221265316289334156

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Fresenius Kabi Oncology Ltd.

Standalone Consolidated
TTM EPS (₹) -3.2 0.9
TTM Sales (₹ Cr.) 660 516
BVPS (₹.) 34.3 15.6
Reserves (₹ Cr.) 566 248
P/BV 3.87 8.50
PE 0.00 140.86
From the Market
52 Week Low / High (₹) 132.00 / 132.60
All Time Low / High (₹) 27.05 / 193.75
Market Cap (₹ Cr.) 2,255
Equity (₹ Cr.) 17
Face Value (₹) 1
Industry PE 40.6

Management X-Ray of Fresenius Kabi Oncol:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Fresenius Kabi Oncol - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Fresenius Kabi Oncol

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales541.56624.01703.48659.57629.87602.59667.27717.14786.43813.05
Operating Expenses 553.36539.64572.43569.14545.94524.13588.60637.93676.91685.51
Manufacturing Costs86.5485.1875.9675.567265.8060.6267.3166.1969.46
Material Costs241.68251.71273.60269.24243.47228.65282.10327.70360.06362.84
Employee Cost 115.61124.43143.21143.47148.39163.60161.53164.72183.28182.56
Other Costs 109.5378.3279.6780.8782.0866.0784.3478.2067.3870.65
Operating Profit -11.8084.38131.0590.4383.9378.4678.6779.21109.51127.55
Operating Profit Margin (%) -2.2%13.5%18.6%13.7%13.3%13.0%11.8%11.0%13.9%15.7%
Other Income 12.7711.6528.2041.8836.2436.2338.1239.0528.4935.20
Interest 29.2136.6345.8636.8039.8937.3116.459.986.739.51
Depreciation 52.1048.7154.8354.6257.8653.7753.0154.0758.8752.05
Exceptional Items -18.62-8.54-40.13-102.23-22.57-369.410000
Profit Before Tax -98.952.1518.42-61.33-0.15-345.7947.3254.2172.41101.19
Tax -16.344.57-1.16-7.41-19.29-9.6311.768.9218.2126.06
Profit After Tax -82.62-2.4219.58-53.9219.14-336.1635.5645.2954.2075.13
PAT Margin (%) -15.3%-0.4%2.8%-8.2%3.0%-55.8%5.3%6.3%6.9%9.2%
Adjusted EPS (₹)-4.9-0.11.2-3.21.2-20.30.70.91.11.6
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 440.53438.35458.17406.84395.6458.531,230.691,279.731,335.241,411.36
Share Capital 17.0217.0217.0217.0216.5216.5248.0448.0448.0448.04
Reserves 423.51421.33441.15389.82379.1242.011,182.651,231.691,287.201,363.32
Minority Interest0000000000
Debt421.25520.80474.47462.87476.50395.8529150.752988.72
Long Term Debt170.38308.46308.46308.46308.46139.4629150.75290
Short Term Debt250.86212.34166.01154.41168.04256.3900088.72
Trade Payables197.60160.89163.96222.22240.89258.14252.17289.64275.2181.51
Others Liabilities 119.56227.40263.34262.38223.63721.50164.08212.12354.05293.06
Total Liabilities 1,178.941,347.431,359.941,354.311,336.651,434.021,675.941,932.251,993.511,874.66

Fixed Assets

Gross Block574.38594.83641.47686.62687.64715.41760.03773.90790.79824.63
Accumulated Depreciation52.03100.57172.75230.14267.82314.31357.28390.48435.20463.92
Net Fixed Assets 522.35494.26468.72456.48419.83401.09402.75383.42355.59360.71
CWIP 30.3944.6437.5537.0224.8325.1738.78135.22157.06171.42
Investments 0.030.030.030.030.030.030.030.030.030.03
Inventories384.41399.50382.23386.01439.13471.51510.39582.18598.69572.83
Trade Receivables133.33142.74162.16149.27153.96223.59355.49381.51350.19380.20
Cash Equivalents 2.348.261.641.970.784.8330.1459.18170.545.39
Others Assets 106.10257.99307.62323.54298.10307.80338.37390.72361.41384.09
Total Assets 1,178.941,347.431,359.941,354.311,336.651,434.021,675.941,932.251,993.511,874.66

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 7.93-39.12111.6398.4177.010.02-459.7523.68174.54-63.76
PBT -98.952.1518.42-61.33-0.15-345.7947.3254.2172.41101.19
Adjustment 88.3969.59119.3196.51114.15103.0561.9564.2965.9249.51
Changes in Working Capital 18.69-110.48-19.8266.68-36.94242.83-568.87-94.6336.8-214.11
Tax Paid -0.20-0.37-6.28-3.46-0.06-0.07-0.15-0.19-0.60-0.34
Cash Flow From Investing Activity -39.16-32.69-28.03-52.21-46.24-44.58-58.89-96.26-57.72-46.22
Capex -36.88-39.51-36.85-54.47-45.54-49.39-59.88-98.98-61.21-48.32
Net Investments 010.221.081.48-0.102.69-0.040.50-1.220.26
Others -2.28-3.407.740.78-0.612.121.032.224.711.85
Cash Flow From Financing Activity -47.58147.43-29-10.05-32.9749.12556.14102.07-6.69-77.73
Net Proceeds from Shares 0000001,134.70000
Net Proceeds from Borrowing 60138.0800029-308.46000
Interest Paid -28.58-30.65-37-33.05-36.23-32.48-18.98-3-4.40-8.48
Dividend Paid 0000000000
Others -79408233.2552.59-251.13105.07-2.29-69.24
Net Cash Flow -78.8175.6254.6036.14-2.214.5637.5029.49110.13-187.70

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-17.16-0.554.37-12.474.77-148.035.523.614.155.47
ROCE (%)-8.054.266.8-2.724.56-40.476.674.775.427.33
Asset Turnover Ratio0.460.50.520.490.470.440.430.40.40.42
PAT to CFO Conversion(x)N/AN/A5.7N/A4.02N/A-12.930.523.22-0.85
Working Capital Days
Receivable Days8379798688114158188170164
Inventory Days239225202213239276269278274263
Payable Days274249217262347398330302286179

Fresenius Kabi Oncology Ltd Stock News

Fresenius Kabi Oncology Ltd FAQs

The current trading price of Fresenius Kabi Oncol on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Fresenius Kabi Oncol stood at ₹2,254.9.
The latest P/E ratio of Fresenius Kabi Oncol as of 31-Dec-1969 is 0.00.
The latest P/B ratio of Fresenius Kabi Oncol as of 31-Dec-1969 is 3.87.
The 52-week high of Fresenius Kabi Oncol is ₹132.6 and the 52-week low is ₹132.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Fresenius Kabi Oncol is ₹659.6 ( Cr.) .

About Fresenius Kabi Oncology Ltd

Dabur Pharma, a leading company for cancer research and oncology drugs, was renamed  Fresenius Kabi Oncology after its acquisition by Fresenius Kabi, the leader in infusion therapy and clinical nutrition in Europe, Latin America, Asia Pacific as well as in the US, where it is a leading supplier of IV generic drugs.

The company markets its products to various part of world namely Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Russia, Ukraine, Georgia, Kazakhstan, Uzbekistan, Hungary, Kenya, Nigeria, Ghana, Zimbabwe, Brazil, Venezuela, Mexico, and many more.

The manufacturing facilities are located in Bordon (U.K.), Kalyani (India) and Baddi (India). These plants are approved by the regulatory bodies of countries like Brazil, Colombia, Malaysia, Turkey, Pakistan, Ukraine, Sudan, Belarus Hungary, Jordan, Zimbabwe, Yemen.

Products

APIs- It manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.

Oncology- Under this it has created drugs like Intaxel, Nanoxel.

Other range of generic products offered by Fresenius Kabi Oncology includes, Taxane Analogues, Alkylating Agents, Anti-Metabolites, Cytostatic Antibiotics, Cytostatic hormone therapies.

You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×